Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
From Transplant to Novel Cellular Therapies in Multiple Myeloma
Abstract: Survival of myeloma patients has greatly improved with the use of autologous stem cell transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. Compared to bortezomib- and lenalidomide-based regimens alone, the addition of high-dose melphalan followed by autologous transplantation significantly improves progression-free survival, although an overall survival benefit was not observed in all trials. Moreover, follow up of recent trials is still too short to show any difference in survival. In the light of these findings, novel agent-based induction followed by autologous transplantation is considered the standard upfront treat...
Clinical Virology
Informs scientists and health care professionals about all the medically relevant aspects of this rapidly evolving field. • Covers novel viruses, pathogenesis, epidemiology, diagnosis, treatment, and prevention. • Addresses infections and syndromes related to particular organ systems, as well as the fundamentals of modern medical virology. • Includes crucial information on immune responses and vaccinology, diagnostics, antivirals, and the nascent field of gene therapy. • Provides agent-specific chapters that detail the virology, epidemiology, pathogenesis, clinical manifestations, and prevention and treatment of important viral pathogens.
Für Ulrich Conrads
None
Cardiovascular Adverse Events in Modern Myeloma Therapy - Incidence and Risks. A Review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Abstract: Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related to the disease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arteriovenous shunting, anemia, renal dysfunction) and/or related to anti-myeloma treatment (anthracyclines, corticosteroids, alkylating agents, immunomodulatory drugs, proteasome inhibitors). Good knowledge of cardiovascular events, effective dose reductions, prevention and management of early and late cardiovascular side effects of chemotherapeutic agents are essential in current clinical practice. Myeloma experts are obliged to carefully balance the efficacy and toxicity of drugs for each individual patient. This review summarizes current data and novel insights into cardiovascular adverse events of today's anti-myeloma treatment, focusing on carfilzomib, as a starting point for developing consensus recommendations on preventing and managing cardiovascular side effects in patients with multiple myeloma
2021 European Myeloma Network Review and Consensus Statement on Smoldering Multiple Myeloma: how to Distinguish (and Manage) Dr. Jekyll and Mr. Hyde
Abstract: According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and
